Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Olympus ( (JP:7733) ) just unveiled an update.
Olympus reported fiscal 2026 revenue of ¥1.01 trillion, up 1.3% year on year, but operating profit from continuing operations fell 40.2% to ¥97.1 billion, with adjusted operating profit down 24%. Profit attributable to owners of the parent dropped 42.2% to ¥68.2 billion, while cash and cash equivalents declined to ¥188.0 billion amid lower operating cash flow and continued investment and financing outflows.
Despite weaker earnings, equity attributable to owners of the parent rose to ¥812.0 billion and the equity ratio improved slightly to 52.8%, supported by total comprehensive income of ¥130.5 billion. The company raised its annual dividend from ¥20 to ¥30 per share and guided for fiscal 2027 revenue of ¥1.055–1.076 trillion and a strong rebound in profit, signaling confidence in profitability recovery after the reclassification of its Orthopedic Business and ongoing portfolio optimization.
The most recent analyst rating on (JP:7733) stock is a Hold with a Yen1700.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.
More about Olympus
Olympus Corporation is a Japanese manufacturer listed on the Prime Market of the Tokyo Stock Exchange, operating primarily in medical technology with a focus on endoscopic and related healthcare equipment. The company reports under IFRS and continues to streamline its portfolio, including classifying its Orthopedic Business as a discontinued operation as part of its strategic realignment.
Average Trading Volume: 6,650,062
Technical Sentiment Signal: Sell
Current Market Cap: Yen1730B
For detailed information about 7733 stock, go to TipRanks’ Stock Analysis page.